Asuragen’s microRNA-based test, miRInform Pancreas, has demonstrated improvements in the diagnosis of pancreatic ductal adenocarcinoma.

The data from the multicentre study involving 186 subjects showed that the miRNA-based molecular test will improve the diagnostic accuracy of fine-needle aspiration cytology on indeterminate and suspicious specimens.

miRInform Pancreas, along with standard fine-needle aspiration cytology, allows pancreatic ductal adenocarcinoma to be diagnosed with 92.5% accuracy, as compared to 80.2% for fine-needle aspiration cytology alone.

Brigham and Women’s Hospital Dr Darwin Conwell said that the microRNA-based molecular test helps to identify false negative cytology.

The molecular test will be available in the company’s CLIA Laboratory from 1 December 2011.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.